API price normalization: Indian manufacturers well placed to reap long-term growth benefits
Post the onset of the pandemic as global pharma manufacturers have realized the necessity to look at supplies outside China. (Photo: Reuters)
2 min read
Share Via
Read Full Story
Indian API (Active Pharmaceutical Ingredient) manufacturers have remained in focus ever since the start of the pandemic. China s supply disruption earlier and rising API prices thereafter have benefitted Indian manufacturers during the past few quarters. Though with normalizing inventories the API prices may normalize in the near term, nevertheless Indian manufacturers remain in a sweet spot and will continue getting opportunities to drive their growth over the long term too.